Old Web
English
Sign In
Acemap
>
authorDetail
>
G. Weems
G. Weems
Irofulven
Medicine
Internal medicine
Oncology
antitumor activity
8
Papers
52
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment
2007
Journal of Clinical Oncology
E.R. Berger
T. Ciuleanu
L. Hart
Kim N. Chi
J. Alexandre
S. Oudard
Carmen Kahatt
G. Weems
E. Cvitkovic
John R. MacDonald
Show All
Source
Cite
Save
Citations (6)
Irofulven (IROF) combined with oxaliplatin (OXA) in advanced hepatocellular carcinoma (HCC) patients (pts): Phase I study (preliminary results)
2006
Journal of Clinical Oncology
François Goldwasser
N Houédé
F.Bertheault Cvitkovic
Misset Jl
Eric Raymond
B. Benettaib
Carmen Kahatt
John R. MacDonald
G. Weems
Show All
Source
Cite
Save
Citations (1)
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
2006
Investigational New Drugs
Werner Hilgers
S. Faivre
Stéphanie Chièze
J. Alexandre
François Lokiec
François Goldwasser
Eric Raymond
Carmen Kahatt
Abdelkrim Taamma
G. Weems
John R. MacDonald
Jean-Louis Misset
Esteban Cvitkovic
Show All
Source
Cite
Save
Citations (13)
Clinical activity of irofulven in hormone refractory prostate cancer
2004
Journal of Clinical Oncology
E. Cvitkovic
Carmen Kahatt
N Senzer
Bertrand Tombal
Stéphane Culine
Eric Raymond
J. Alexandre
G. Weems
John R. MacDonald
Show All
Source
Cite
Save
Citations (2)
Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results
2004
Journal of Clinical Oncology
S. Falcon-Lizaraso
J. Leon-Chong
F. Perazzo
François Goldwasser
A. Cohn
Carmen Kahatt
G. Weems
S G Eckhardt
Show All
Source
Cite
Save
Citations (8)
1